A randomized, double-blind, placebo controlled, parallel group, Phase II multi-centric trial to assess safety, tolerability and efficacy of PHD-2 Inhibitor, ZYAN1 in the treatment of anemia in pre-dialysis chronic kidney disease patients.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Desidustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Cadila Healthcare
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.
- 31 May 2017 New trial record